CompletedPhase 2/3

MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD)

United States31 participantsStarted 2021-04-06

Plain-language summary

This proposal will measure the effects of mannitol administration versus placebo in hypotensive-prone, adult, maintenance hemodialysis patients with respect to changes in patient symptoms and blood pressure stability.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Maintenance HD (\>90 days) * Age ≥18y * Thrice-weekly HD * IDH-prone (defined as nadir intra-dialytic SBP \<100 mmHg in ≥30% of sessions in the prior 4 weeks) * Hematocrit\>21% * Written informed consent Exclusion Criteria: * Acute myocardial infarction or stroke within one month * Pre-HD serum potassium \>6.5 mmol/L in last 4 weeks * Pregnancy * Institutionalized individuals * Life expectancy \<2 months * Planned renal transplant within 2 months * Active enrollment in another interventional trial * Known allergy to mannitol

What they're measuring

Patient Symptoms

Timeframe: 4 weeks

Trial details

NCT IDNCT04428372

SponsorBrigham and Women's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

View on ClinicalTrials.gov More Hemodialysis Complication trials